Tagged with AI

pharma The minister of health reveals how for the first time in the country´s history the healthcare sector is following a clear roadmap with the National Development Plan, a vision for where the country should be in 2030, how the National Health Initiative will mean a total reconstruction of the healthcare…

pharma Francisco García was appointed as the executive director for the Puerto Rico Manufacturers Association (PRMA) in August 2015. He stresses the importance of developing Puerto Rico’s entrepreneurial talent and startup clusters as his main initiatives. As you have recently taken over as executive director of PRMA, could you outline the…

pharma Jörg Buck, the Executive Director of the Italian-German Chamber of Commerce discusses the close trade relationship which ties the two countries together, how the business environment in Italy is evolving today and the need to keep the momentum in the economic recovery. To start off, having joined the chamber recently,…

pharma Egypt is back in business, with economic growth and investor confidence in Egypt nearly back to levels seen in 2010, GDP growth up to four percent, and several high profile deals with multinationals. PharmaBoardroom spoke to Hisham A Fahmy, the CEO of the American Chamber of Commerce, about keeping Egypt…

Algeria PharmaBoardroom recently conducted a roundtable event with the key opinion leaders of Algeria’s healthcare sector. This is a sample of the conversation at our recent roundtable. Algeria’s youthful pharmaceutical landscape includes an array of state-controlled entities of an industrial or commercial nature alongside more conventional regulatory apparatus.  THE NATIONAL AGENCY FOR…

Pharma The Center for Pharmaceutical Engineering and Learning (CPEDaL) was established in 2006 as a ten year training program that is currently awaiting funding for the next five years. Carlos Velázquez, director of CPEDaL, explains how the Center introduces high school students to pharmaceutical engineering and their pioneering work in mixing…

pharma Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the pharmaceutical industry. To begin, Dr. Özgören, could you give us an overview of the intent behind the BioIzmir project? The…

Thailand Thailand is not traditionally known to be a manufacturing center due to its ever-changing policies, but OLIC (Thailand) Limited has risen as the nation’s number one contract manufacturing organization (CMO). OLIC’s managing director, Toyoyuki Kamide, talks about the company’s new manufacturing facility, its merger with Fuji Pharma, and its status…

Thailand The Government Pharmaceutical Organization’s Managing Director, Dr. Nopporn Cheanklin, tells PharmaBoardroom about its plans to launch 20 new products, its seaarch for medicines whose patents expire in the next few years, and the prospects for exports to Laos, Cambodia and Myanmar. What ambitions for growth does the organization have both in Thailand…

Thailand Pfizer is now the number one pharmaceuticals company in Thailand. We spoke to Christian Malherbe, Country Lead for IndoChina, which includes Myanmar, Laos, and Cambodia, about how he is making the management structure flatter and continuing to bring new medicines to the region.   In the future, we see our…

universal healthcare Berlin Pharmaceutical Industry’s CEO, Amal Naj, explains how he has grown the company, its next regional and medical targets, and his vision for its future. What has led to Berlin Pharmaceutical’s success over the last five years?    In 2010, the market was going through a major transition due to the progressive…

government PharmaBoardroom met the Secretary General of the Thai FDA and the Senior Expert on Pharmaceutical Standards at the FDA. They explained the FDA’s role in Thailand’s pharma market, what the organization is doing for Thai copyright rights, how it is promoting international investment and integration within the ASEAN Economic Community. Please introduce…